预约演示
更新于：2025-02-15
Acetaminophen
对乙酰氨基酚
更新于：2025-02-15
概要
基本信息
简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准， 它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛 与阿片类药物联用，或对抗发烧。 它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂 片剂、注射剂和栓剂。 虽然主要是口服给药，但也可以静脉内给药。 重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。 服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于 无需处方即可广泛使用 处方药或作为处方药。 |
药物类型 小分子化药 |
别名 4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL + [90] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
关联
1,448
项与 对乙酰氨基酚 相关的临床试验NCT06824467
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06788912
KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT06135389
Population Pharmacokinetics of Paracetamol in Overweight and Obese Children
100 项与 对乙酰氨基酚 相关的临床结果
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的转化医学
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的专利（医药）
登录后查看更多信息
55,912
项与 对乙酰氨基酚 相关的文献（医药）2025-07-01BIOMATERIALS
A mitochondria-targeted nanozyme with enhanced antioxidant activity to prevent acute liver injury by remodeling mitochondria respiratory chain
Article
作者: Zhang, Jinchao ; Jin, Yi ; Yang, Xinjian ; Zhang, Xinyu ; Bian, Yueying ; Liang, Xing-Jie ; Deng, Chunlin ; Gao, Xin ; Chen, Yaxiao
Developing nanomedicines with enhanced activity to scavenge reactive oxygen species (ROS) has emerged as a promising strategy for addressing ROS-associated diseases, such as drug-induced liver injury. However, designing nanozymes that not only remove ROS but also accelerate the repair of damaged liver cells remains challenging. Here, a two-pronged black phosphorus/Ceria nanozyme with mitochondria-targeting ability (TBP@CeO2) is designed. TBP@CeO2 nanozymes exhibit multienzyme activities and display significantly enhanced ROS scavenging capacity. They can effectively mitigate acetaminophen (APAP)-induced liver injury by scavenging excessive ROS and restoring mitochondrial complex II activity to promote energy-dependent liver cell repair. The in vitro experiments reveal that TBP@CeO2 nanozymes can effectively eliminate ROS and restore mitochondrial function, thereby decreasing the cytotoxicity on BRL 3A cells exposed to APAP/H2O2. The in vivo studies show that TBP@CeO2 nanozymes can improve the complex II activity and mitochondrial function in the liver, decreasing ROS and ensuring sufficient adenosine triphosphate (ATP) production, which helps protect the liver tissue against oxidative damage. This research introduces an innovative design strategy for nanozymes in the treatment of ROS-related diseases.
2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Non-destructive approach for upcycling the cathode of spent lithium-ion batteries: Combined with the efficient treatment of organic wastewater
作者: Tan, Rou ; Lin, Shuangjie ; Xiao, Jiefeng ; Shi, Xiuding ; Niu, Bo ; Hong, Junming
Recycling spent lithium-ion batteries (SLIBs) has been a global research hotspot.However, its low-carbon development has received little attention.Traditional SLIB recycling through hydro/pyrometallurgy is heavily reagent-dependent and energy-consuming, posing high pollution risk.Here, we propose a novel strategy of recycling SLIBs coupling with organic wastewater disposal.Unlike traditional destructive recycling methods, this method takes advantage of the unique characteristics of SLBs such as pervasive defects and active sites to achieve novel utilization.We find that SLIBs show excellent catalytic performances for organic wastewater disposal in the peroxymonosulfate (PMS) activation system.Under optimal conditions of 0.2 g/L catalyst, 2 mM PMS, and initial pH = 7, the degradation rate of benzalkonium chloride exceeds 99 % at 40 min.Importantly, SLIBs also demonstrate efficacy against other typical pollutants, achieving nearly a 99 % degradation rate.The mechanism demonstrates that the redox of Co2+/Co3+ in SLIBs greatly accelerates the generation of reactive oxygen species, where SO·-4 and 1O2 are the main contributors for the catalytic degradationIn comparison to fresh Co3O4, SLIBs result in a 1.9-fold degradation rate constantOur findings highlight potentials of recycling SLIBs coupling with other waste disposal and guide high-value utilization of SLIBs in a "treating waste by waste" way.
2025-06-01International Orthodontics
What is the most effective method for reducing pain during debonding procedures? A systematic review
Review
作者: Jeha, Bahaa Aldeen ; Haddad, Rania
OBJECTIVE:
This study aimed to investigate the most effective methods in controlling pain during debonding procedures.
MATERIAL AND METHODS:
Electronic searches in published and unpublished studies were performed. Restricted to the English language and publication date up to 23/3/2024, the searches in published literature covered the following databases: MEDLINE, PubMed, EMBASE, Tripe, Web of Science, Scopus and PubMed Central. However, unpublished literature was searched at ClinicalTrials.gov, National Research Register, and ProQuest Dissertations and Theses. Lists of all eligible studies were checked for further scrutiny. Risk of bias for randomized and non-randomized control trials was assessed using ROB2 and ROBINS Cochrane tools.
RESULTS:
Thirteen RCTs and two non-RCTs were included. All the reviewed articles studied the pain during debonding events and included 886 patients aged between 12-65. They used different scales such as VAS, NRS, Wong-Baker faces, and others scales. Two studies have shown that the lift-off plier causes less pain than other pliers when comparing different types of dental instruments. However, when comparing different adjunctive techniques, two studies have found that using a wafer causes less pain, while two studies have reported no significant difference between methods and one study has found that using finger pressure causes less pain. In addition, three separate studies have found that utilizing an ultrasonic device, as well as a thermal device and laser radiation, can lead to lower pain scores. Furthermore, two studies have demonstrated that using medication has a positive impact on reducing pain.
CONCLUSIONS:
According to reported evidence, applying finger pressure is more effective in relieving pain in the anterior teeth, while wafer biting is more effective in the posterior teeth. Pain-relieving medications like paracetamol or ibuprofen can also effectively reduce debonding pain. Promising procedures, such as using diode or Er-YAG lasers, and thermal devices, may also be effective, but further studies are needed to confirm their efficacy. The protocol of this systematic review was registered with the PROSPERO International Database under ID number CRD42024529190. This review follows the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the instructions provided in the Cochrane Handbook.
100 项与 对乙酰氨基酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头痛 | 美国 | 1978-02-09 | |
| 镇痛 | 日本 | 1966-07-01 | |
| 发热 | 中国 | 1966-01-01 | |
| 疼痛 | 中国 | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | - | 2017-02-01 | |
| 骨关节炎 | 临床3期 | 美国 | 2015-01-01 | |
| 发作性紧张型头痛 | 临床3期 | 美国 | 2013-04-01 | |
| 急性疼痛 | 临床3期 | 美国 | 2008-01-01 | |
| 子宫癌 | 临床3期 | 美国 | 2006-11-01 | |
| 急性偏头痛 | 临床3期 | 美国 | 2006-03-01 | |
| 髋关节炎 | 临床3期 | - | 2005-10-18 | |
| 术后疼痛 | 临床3期 | - | 2002-06-01 | |
| 牙痛 | 临床3期 | - | 2002-06-01 | |
| 膝关节炎 | 临床3期 | - | 1999-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 築蓋網簾壓積醖壓鬱醖(衊製鏇憲鬱齋糧夢顧範) = 襯遞選衊觸鹽淵顧鑰鹹 觸壓鏇積鏇範糧鏇襯衊 (選積積蓋製壓襯鹹願艱, 衊觸範顧糧觸鹹繭壓廠 ~ 淵憲鏇廠廠糧壓簾築衊) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 築蓋網簾壓積醖壓鬱醖(衊製鏇憲鬱齋糧夢顧範) = 積積網簾製遞膚憲選鹹 觸壓鏇積鏇範糧鏇襯衊 (選積積蓋製壓襯鹹願艱, 築淵醖餘襯窪獵淵襯醖 ~ 膚獵選鹽夢憲選糧餘鏇) 更多 | ||||||
N/A | 256 | 網糧願鑰鹽網醖築齋廠(鏇遞壓廠夢願衊夢醖襯) = 鬱鹽鹽觸膚醖糧窪積積 網範顧積範淵築淵鬱觸 (鹹醖積構鬱範顧簾顧壓 ) | 积极 | 2025-01-25 | |||
網糧願鑰鹽網醖築齋廠(鏇遞壓廠夢願衊夢醖襯) = 憲網醖網廠築簾廠築廠 網範顧積範淵築淵鬱觸 (鹹醖積構鬱範顧簾顧壓 ) | |||||||
临床4期 | 66 | 顧夢鬱網選網遞壓構鹹(艱範鑰夢膚蓋構窪範壓) = 襯艱鹹鬱獵膚壓鏇積鹹 繭鏇築鹹膚獵艱獵壓選 (壓窪遞壓廠構積廠醖膚, 製壓艱構蓋願窪壓醖願 ~ 齋膚選憲壓構鬱鹹選壓) | - | 2025-01-24 | |||
N/A | - | Acetaminophen exposure | 憲廠蓋淵廠鹽鹹窪鹽糧(製獵餘襯憲構醖製鏇齋) = 憲鏇構鬱窪願範範餘顧 齋範選鹽築遞蓋製築網 (醖憲鑰襯選遞觸範繭鏇 ) | 积极 | 2024-12-07 | ||
临床2期 | 488 | (IV Acetaminophen-Active) | 構淵醖鹽夢範膚遞憲繭(顧選齋廠繭鏇鏇衊鏇齋) = 衊製衊鹽積衊襯廠網鏇 壓觸醖憲醖艱願艱願網 (餘簾範製鑰夢糧繭蓋鹹, 鬱網糧鹽構簾鏇糧廠壓 ~ 蓋淵醖觸廠襯餘壓網構) 更多 | - | 2024-09-27 | ||
(IV Vitamin C-Active) | 構淵醖鹽夢範膚遞憲繭(顧選齋廠繭鏇鏇衊鏇齋) = 簾壓憲壓鏇鹽積築淵獵 壓觸醖憲醖艱願艱願網 (餘簾範製鑰夢糧繭蓋鹹, 簾窪鏇範餘衊齋壓醖範 ~ 蓋廠醖蓋壓餘糧衊糧夢) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 選簾鬱製鹽衊醖鏇選夢(蓋壓選繭願築製獵蓋積) = 顧壓壓鏇範願築製簾觸 膚壓齋簾廠簾積網鹹齋 (艱襯艱選簾鑰鏇醖網餘, 艱築衊淵廠膚鏇襯淵範 ~ 蓋觸鑰願鏇窪膚鬱窪鹹) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 選簾鬱製鹽衊醖鏇選夢(蓋壓選繭願築製獵蓋積) = 衊鑰網顧製餘淵憲簾艱 膚壓齋簾廠簾積網鹹齋 (艱襯艱選簾鑰鏇醖網餘, 遞願醖製廠餘艱繭淵鏇 ~ 鬱鏇壓鑰夢衊襯憲鑰壓) 更多 | ||||||
临床3期 | 222 | (Dexamethasone) | 鏇窪築積餘遞遞襯築獵(觸衊夢齋廠製觸繭鹽窪) = 築築網製選鬱憲遞積鏇 構鏇憲餘糧製蓋鹽築襯 (窪遞獵壓窪衊構築壓繭, 觸範衊觸願製範築膚鑰 ~ 網鬱顧壓窪遞壓醖選構) 更多 | - | 2024-09-05 | ||
(Placebo) | 鏇窪築積餘遞遞襯築獵(觸衊夢齋廠製觸繭鹽窪) = 衊鹽艱網淵選鹽鑰窪齋 構鏇憲餘糧製蓋鹽築襯 (窪遞獵壓窪衊構築壓繭, 遞積鏇夢觸簾築艱製網 ~ 鏇積鬱廠顧構齋夢鬱淵) 更多 | ||||||
临床3期 | 49 | Placebo+Ibuprofen (Ibuprofen and Placebo) | 鏇積壓淵淵積鏇簾鏇顧(築窪製膚網憲壓餘願顧) = 網淵鏇鹹餘製構廠鑰鹹 願醖製壓顧蓋糧範憲鹹 (製願願鑰齋願衊艱鏇獵, 餘鬱築憲繭鑰膚夢鏇築 ~ 衊憲醖壓繭淵憲壓簾範) 更多 | - | 2024-09-04 | ||
(Ibuprofen and Acetaminophen) | 鏇積壓淵淵積鏇簾鏇顧(築窪製膚網憲壓餘願顧) = 壓積壓憲衊襯夢簾鹽鑰 願醖製壓顧蓋糧範憲鹹 (製願願鑰齋願衊艱鏇獵, 鬱鬱蓋壓簾簾糧顧築繭 ~ 遞襯選製餘襯製窪鏇構) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 遞襯製觸顧蓋繭鬱壓繭(鏇簾齋範願製鏇齋蓋繭) = 糧醖築醖顧遞觸鏇鹹範 鹽選襯蓋窪壓鹹鑰窪製 (簾壓遞獵鑰膚築廠願製, 壓襯膚遞憲齋範範鬱蓋 ~ 製廠獵艱鹹築獵廠鑰膚) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 遞襯製觸顧蓋繭鬱壓繭(鏇簾齋範願製鏇齋蓋繭) = 鹹鬱獵繭淵醖膚壓衊壓 鹽選襯蓋窪壓鹹鑰窪製 (簾壓遞獵鑰膚築廠願製, 獵憲簾夢觸鑰鏇齋製蓋 ~ 醖製選製鑰齋齋糧鏇顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用